Korea Exchange · Healthcare
Hanall Biopharma stock from India: price, numbers and tax
Hanall Biopharma (009420) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Hanall Biopharma at a glance
- Price
- ₩44,000.00-₩1,800.00 (3.93%)
- Market cap
- ₩2.24T
- Day range
- ₩43,650.00 – ₩45,200.00
- P/E
- -91.27
- Dividend yield
- None
- Volume
- 234.51K
- 1 month
- -16.35%
- 6 months
- -6.68%
- YTD
- +0.57%
- 1 year
- +25.89%
- 5 years
- +121.11%
Hanall Biopharma statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩155.2B | ₩138.9B | ₩134.9B | ₩110.0B | ₩101.6B |
| Gross profit | ₩79.1B | ₩73.3B | ₩75.0B | ₩62.0B | ₩60.3B |
| Operating income | −₩1.6B | ₩230.5M | ₩3.1B | ₩1.5B | ₩10.1B |
| Net income | −₩5.6B | −₩1.8B | ₩3.5B | ₩251.5M | ₩8.9B |
| Earnings per share | −₩111.55 | −₩35.59 | ₩69.21 | ₩4.95 | ₩173.74 |
| EBITDA | ₩1.9B | ₩3.4B | ₩6.6B | ₩5.0B | ₩11.5B |
| Total assets | ₩225.2B | ₩212.9B | ₩239.7B | ₩213.5B | ₩198.5B |
| Total debt | ₩31.9B | ₩1.4B | ₩1.3B | ₩1.3B | ₩1.3B |
| Cash and short-term investments | ₩24.7B | ₩24.7B | ₩56.5B | ₩53.9B | ₩80.6B |
| Shareholders' equity | ₩161.7B | ₩168.4B | ₩186.2B | ₩168.3B | ₩163.5B |
| Operating cash flow | −₩2.3B | ₩9.4B | ₩29.6B | ₩25.2B | ₩839.9M |
| Free cash flow | −₩3.3B | −₩13.7B | ₩20.4B | ₩17.5B | −₩8.2B |
| Capital expenditure | −₩948.0M | −₩23.1B | −₩9.2B | −₩7.7B | −₩9.0B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Hanmi Pharm. | 128940.KS | ₩480,500.00 | ₩6.09T |
| Celltrion Pharm | 068760.KQ | ₩38,800.00 | ₩1.72T |
| GC Biopharma | 006280.KS | ₩129,400.00 | ₩1.48T |
| Chong Kun Dang Pharmaceutical | 185750.KS | ₩65,900.00 | ₩868.30B |
| Boryung | 003850.KS | ₩8,610.00 | ₩727.38B |
| HLB Pharmaceutical | 047920.KQ | ₩13,130.00 | ₩430.65B |
| Huons Global | 084110.KQ | ₩23,100.00 | ₩281.96B |
| BINEX | 053030.KQ | ₩6,340.00 | ₩201.91B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Hanall Biopharma from India
What Hanall Biopharma does
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. Hanall Biopharma operates in the Medical - Pharmaceuticals industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Hanall Biopharma shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.